CAS · 96829-58-2
Product Overview
Orlistat is a high-purity a-api supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.
Product Specifications
| Appearance | White or almost white crystalline powder |
|---|---|
| Assay | 98% min (on anhydrous) |
| Specific rotation | -48° ~ -51° |
| Identification | HPLC/IR Complies |
| Solution | Very soluble in methanol and ethanol, freely soluble in chloroform, practically insoluble in water |
| Melting point | 42 ~ 46°C |
| Any other single impurity | 1.0% max |
| Total impurities | 2.0% max |
| Methanol | 3000 ppm max |
| Ethanol | 5000 ppm max |
| Acetonitrile | 410 ppm max |
| Heptane | 5000 ppm max |
| Water | 0.5% max |
| Pd | 5 ppm max |
| Residue on ignition | 0.1% max |
| Heavy metals | 20 ppm max |
| Total aerobic count | 900 CFU/g max |
| Moulds and yeasts | 90 CFU/g max |
| Escherichia coli | Negative |
Applications
Orlistat (CAS 96829-58-2) is a well-known pharmaceutical compound primarily used as an anti-obesity drug. Its main application is in the treatment and management of obesity, often prescribed alongside a reduced-calorie diet and lifestyle modifications. Orlistat works locally in the gastrointestinal tract by inhibiting gastric and pancreatic lipases, the enzymes responsible for breaking down dietary fats into absorbable free fatty acids and monoglycerides. As a result, approximately 30% of ingested fat is not absorbed and is instead excreted, reducing overall calorie intake. It is commonly formulated in capsule form for clinical use and is approved in many countries for long-term weight management. Beyond obesity, Orlistat is sometimes applied off-label in conditions where reduced fat absorption may be beneficial, such as certain metabolic disorders.
Benefits
The benefits of Orlistat are strongly associated with its mechanism of action and clinical outcomes. It provides a non-systemic approach to weight management, as it acts locally in the digestive system without significant systemic absorption, reducing the risk of systemic side effects. By lowering fat absorption, it helps patients achieve meaningful weight loss when combined with dietary changes, which in turn reduces risk factors associated with obesity, such as hypertension, type 2 diabetes, dyslipidemia, and cardiovascular disease. Orlistat also supports improved glycemic control in overweight or obese patients with type 2 diabetes, contributing to better overall metabolic health. Its long-term use, when medically supervised, can help patients sustain weight reduction, improve quality of life, and reduce obesity-related health complications.
Conclusion
In conclusion, Orlistat is an effective pharmaceutical agent for managing obesity and supporting weight-related health improvements. Its localized mechanism of action, ability to aid in clinically significant weight loss, and positive effects on obesity-related comorbidities make it a cornerstone in pharmacological weight management strategies. By complementing dietary and lifestyle interventions, Orlistat offers patients a practical and evidence-based option for achieving sustainable improvements in both body weight and overall health.
Previous
Next